Health and Fitness Health and Fitness
Wed, July 13, 2011
Tue, July 12, 2011
Mon, July 11, 2011
Sun, July 10, 2011
Sat, July 9, 2011
Fri, July 8, 2011
Thu, July 7, 2011
Wed, July 6, 2011
[ Wed, Jul 06th 2011 ] - Market Wire
Larry Renfro Named CEO of Optum
Tue, July 5, 2011
Mon, July 4, 2011
Sat, July 2, 2011
Fri, July 1, 2011
Thu, June 30, 2011
[ Thu, Jun 30th 2011 ] - Market Wire
KCI???NPWT????????????
Wed, June 29, 2011
Tue, June 28, 2011
Mon, June 27, 2011
Sat, June 25, 2011
Fri, June 24, 2011
Thu, June 23, 2011
Wed, June 22, 2011
Tue, June 21, 2011
Mon, June 20, 2011
Sun, June 19, 2011
Fri, June 17, 2011
Thu, June 16, 2011

University of Washington Department of Genome Sciences Joins Illumina Genome Network


//health-fitness.news-articles.net/content/2011/ .. nome-sciences-joins-illumina-genome-network.html
Published in Health and Fitness on Wednesday, June 29th 2011 at 3:41 GMT by Market Wire   Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Illumina, Inc. (NASDAQ:ILMN) today announced that the University of Washington (UW) Department of Genome Sciences has joined the Illumina Genome Network (IGN). IGN is a global partnership designed to link researchers seeking large-scale whole human genome sequencing services with leading institutions that provide such services using Illuminaa™s sequencing technology.

"Illumina believes making whole genome sequencing more accessible to researchers worldwide is fundamental to enhancing our understanding of human biology and making breakthrough medical advances"

Recent advancements in Illumina HiSeqa" sequencing system technology have enabled the company to lower the price for the service to $5,000 per genome for projects of 10 samples or more, and $4,000 for projects of 50 samples or more. By offering the speed, accuracy and high-quality data researchers require at price points they can afford, the Illumina Genome Network has raised the bar on whole human genome sequencing services.

aIllumina believes making whole genome sequencing more accessible to researchers worldwide is fundamental to enhancing our understanding of human biology and making breakthrough medical advances,a said David Bentley, Vice President and Chief Scientist at Illumina. aWe are very pleased that the University of Washingtona™s Genomic Sciences Department, one of the worlda™s leading genomic research facilities, now will make its state-of-the-art capabilities broadly available via the Illumina Genome Network.a

Formed in 2001, the UW Department of Genome Sciences has used Illumina systems since 2008; its goal is to apply genetic, genomic and computational approaches to todaya™s leading questions in biology and medicine.

All Illumina Genome Network partners are experienced and well-published using Illumina sequencers, and have completed Illuminaa™s CSPro® (Certified Service Provider) certification. Each has 10 or more Illumina sequencing systems (Genome Analyzers and/or HiSeq 2000 systems) in their facility, providing the scalability to handle even the largest sequencing projects and the speed to provide data as quickly as possible. The UW Department of Genome Sciences joins the National Center for Genome Resources, Macrogen/Genomic Medicine Institute, and Illuminaa™s own FastTrack Services as members of the Illumina Genome Network.

About Illumina

Illumina ([ www.illumina.com ]) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.


Publication Contributing Sources